Australian innovation in action.
2025 will see an incredible range of Australian biotech innovators take to the stage on 21 October as they aim to impress the audience of investors, experts and peers.
Here you can learn more about these companies and start to get to know them.
Amplia Therapeutics Limited (ASX: ATX)
An Australian, clinical-stage drug development company focused on creating potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.
The company’s pipeline drugs were developed through an Australian industry/academic collaboration with leading cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialization.
Amplia’s Board and Management teams are composed of highly experienced life-science executives with extensive international experience in drug development, pharmaceuticals, and deal-making.
Arovella Therapeutics (ASX: ALA)
Arovella Therapeutics is a pre-clinical-stage biotechnology company pioneering a first-in-class, ‘off-the-shelf’ (allogeneic) cell therapy platform leveraging invariant Natural Killer T (iNKT) cells to treat cancer. The company’s core focus is on developing next-generation therapies for both haematological malignancies and solid tumours. Its lead asset, ALA-101, is a CAR-iNKT therapy targeting the clinically validated CD19 antigen for B-cell lymphomas and leukemias.
Arovella is strategically expanding into high-unmet-need solid tumours by targeting Claudin 18.2 (CLDN18.2), a validated antigen in gastric and pancreatic cancers. The company intends to integrate its IL-12-TM cytokine ‘armouring’ technology into its solid tumour programs, which is designed to enhance potency by overcoming the immunosuppressive tumour microenvironment.
Arovella aims to deliver therapies with superior efficacy, a favourable safety profile, and improved patient access compared to current standards of care.
BiomeBank
BiomeBank has delivered a series of world-first achievements and built a strong foundation for growth.
This foundation includes:
- The first-ever regulatory approval of a donor-derived microbiome therapy (Biomictra®) generating revenue and drug discovery data from clinical trials
- The world’s most diverse culture collection of microbes from screened human donor
- Microbiome drug discovery platform with unprecedented, unique and defensible ability to co-culture the most prevalent bacteria in a healthy human microbiome, containing over 90% of know gene families in a healthy human microbiome.
- Diversified portfolio and risk by leveraging platform for development of both live bacterial therapeutics (pharmaceuticals) and consumer health focused probiotics.
- Highly differentiated microbiome therapy for ulcerative colitis (BB265) entering phase 1b human trial in 2025.
Blinklab
Based at Princeton University, BlinkLab was founded by neuroscientists to develop a smartphone-based diagnostic platform for autism and ADHD.
Their flagship product is a diagnostic test for autism, specifically designed for children as young as 18 months. This is a significant breakthrough, as traditional diagnoses often don’t occur until around five years of age, missing a key window for early intervention.
BlinkLab is led by an experienced team with a proven track record in digital healthcare and AI, supported by a Scientific Advisory Board of top experts in brain development and autism.
Chimeric Therapeutics
Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.
Exosome Biosciences
Exosome BioSciences (EBS) is a biotech start-up company spun out of the Hudson Institute of Medical Research and Monash University. Comprised of world-leading medical researchers and clinicians, EBS hosts over 20 years of expertise in regenerative medicine and translational therapeutics.
Exosomes are chemical messengers produced by all cell types. EBS has identified and characterised specific exosomes that possess potent anti-inflammatory and regenerative properties. By harnessing the bioactivity of these exosomes, EBS has developed a novel therapy for inflammatory and fibrotic disease, including inflammatory bowel disease, chronic liver disease and bronchopulmonary dysplasia.
Through established methods of manufacture, robust preclinical validation and translation into clinical practice, EBS has developed a safe, scalable, and effective exosome therapy that may provide a lasting solution for many different diseases the world over.
Filamon
Filamon was founded by three Australian scientists with extensive clinical and drug development experience in the fields of cancer and chronic inflammatory diseases, frustrated at the lack of significant progress across a wide range of common causes of death and disability and recognising that a new approach to drug development was required. The bourgeoning so-called ‘baby-boomer’ market has only intensified the need for accessible treatments for multiple complex, age-related diseases.
The Filamon scientific rationale is that chronic age-related diseases are complex disease processes involving hundreds of different genes which the modern era of precision medicine, designed to target as few genes as possible, has not adequately succeeded doing.
Filamon believes that complex diseases require complex-acting drugs.
Filamon has curated three novel technology platforms, each designed to deliver broad-based therapeutic benefits in a well-tolerated and cost-effective way.
Filamon is a public, unlisted company currently focused on the development of breakthrough drugs for chronic, age-related diseases including cancer, macular degeneration, cardiovascular diseases and neurodegenerative diseases including dementias.
HaemaLogiX
HaemaLogiX is a clinical stage Australian biotechnology company, advancing a pipeline of next generation immunotherapies for blood cancers and B-cell disorders.
The company’s key focus is multiple myeloma: the second most common haematological cancer.
About HaemaLogiX:
– Assets in two major drug classes – monoclonal antibodies and CAR T cell therapies
– Compelling results – in the Company’s Phase 1, 2a and 2b trials completed for lead immunotherapy, KappaMab. HaemaLogiX’s immunotherapies have shown the potential to enhance the current standard-of-care and offer a compelling combination treatment option for patients diagnosed with a disease that currently has no cure
– Large and growing market – two lead assets, KappaMab and KMA.CAR-T cell target the largest and fastest-growing patient segments of the US$23 billion multiple myeloma market.
– Competitive advantage – unlike other drugs, HaemaLogiX’s immunotherapies target cancer cells while sparing normal plasma cells, enabling normal immune response to fight infection.
Humble Bee Bio
Humble Bee Bio presents a transformative opportunity in the rapidly growing anti-aging market through HBB02, a breakthrough molecule derived from patented bee genome sequences that increases elastin production by over 500% compared to existing alternatives.
Invion (ASX: IVX)
Invion is a clinical-stage company developing Photosoft™, a next-generation Photodynamic Therapy for cancers and infectious diseases. Early Phase I/II trial data for non-melanoma skin cancer showed a strong safety profile and reduced lesion sizes. A Phase II prostate cancer trial also showed a 40% response rate.
Invion plans more cancer trials, including one for anogenital cancer with the Peter MacCallum Cancer Centre. The company also has agreements with partners to fund studies for brain malignancy, esophageal cancer, and HPV. Preclinical results have shown the technology can completely regress various cancers and stimulate the immune system.
ISOBiotech
ISOBiotech is a rapidly emerging Australian start-up revolutionising the field of molecular diagnostics. Backed by nearly two decades of expertise, they have developed a proprietary isothermal amplification technology – Isothermal PCR Amplification (IPA™) – that delivers rapid, accurate, and scalable detection of any known infectious disease.
At the core of their innovation is IPA™, a novel amplification chemistry that pairs seamlessly with their compact, easy-to-use diagnostic platform, the RapidDetector™. Together, they enable fast, reliable, and decentralised testing, without the need for complex instrumentation or laboratory infrastructure.
ISOBiotech’s In Vitro Diagnostic (IVD) intended solutions, certified to ISO13485:2016 standards, can transform the way infectious diseases are detected, monitored and managed, by empowering clinicians and public health systems with tools that are accurate, affordable, and accessible. Their technology is well-suited to meet global demands for point-of-care diagnostics, especially in resource-limited settings or during health emergencies such as epidemics and pandemics.
Myopharm Limited
Myopharm is developing targeted therapies for multiple chronic diseases, using a multifaceted approach to development. A clinical-stage Australian-based biopharmaceutical company, Myopharm has pharmaceutical drug candidates & clinically validated consumer health products in their portfolio.
Myopharm is dedicated to creating and maintaining collaborative partnerships with best-in-class institutions. They currently work with a number of universities, endocrinologists, and nutrition specialists globally.
NeuroScientific Biopharmaceuticals (ASX: NSB)
NeuroScientific Biopharmaceuticals (ASX: NSB) is an innovative biotechnology company developing stem cell therapies using its patented StemSmart manufacturing technology to treat patients with Crohn’s disease and other severe inflammatory auto-immune disorders.
Prescient Therapeutics (ASX: PTX)
Prescient Therapeutics is a clinical-stage oncology company developing targeted therapies. Its lead drug, PTX-100, is a first-in-class targeted therapy and potentially the world’s only GGT-1 inhibitor.
It is currently in a Phase 2a clinical study for Cutaneous T Cell Lymphoma and has received both Fast Track and Orphan Drug Designation from the US FDA. The company also holds exclusive rights to two next-generation cell therapy platforms, OmniCAR and CellPryme, which are designed to enhance CAR-T therapies.
QBiotics
QBiotics is an Australian clinical stage life sciences company specialising in discovery and development of small molecules to treat complex medical conditions. The initial focus is on oncology and wound healing.
QBiotics’ lead asset, tigilanol tiglate, is an intratumourally-delivered drug that can rapidly destroy solid tumours with a single injection.
Currently in Phase IIa clinical trials in two indications:
- Soft Tissue Sarcomas (STS), having received Orphan Drug Designation (ODD) from the US FDA; and
- Head and neck cancers (HNC).
A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for treating canine mast cell tumours, in the USA, Europe, UK and Australia and distributed by Virbac, a global animal health company.
QBiotics’ second candidate, EBC-1013, is a small molecule which, delivered topically, targets multiple pathways to accelerate healing, with potential to treat a wide range of chronic wounds and burns. A Phase I clinical trial for patients with venous leg ulcers is underway.
S2N
S2N is pioneering autologous cell therapies for Alzheimer’s and other neurological diseases.
Based on the discovery of unipotent precursor cells in the hair follicle that can only become neurons.
When injected into the hippocampus, these cells safely and durably reconstitute lost hippocampal neural networks and restore memory function.
Unique preclinical package in the only valid model of AD: the dog. In veterinary clinical trial, we show a 9 SD increase in synapses and profound, durable improvements in cognition in pet dogs with confirmed Alzheimer Pathology.
No pluripotency or gene modifications means minimal risk of oncogenesis and a simple regulatory path.
Simple, reliable, scalable, rapid, & inexpensive cell manufacture. Closed manufacture in Miltenyi Prodigy. CoGs and Needle-to-Needle a small fraction of their competition.
Additional programs differentiate the neuronal precursor cells for Rx of Parkinson, Epilepsy and Huntington with major competitive advantages over BlueRock, Aspen, and Neurona.
Tiba Biotech
Tiba Biotech has built strong momentum through a combination of competitive grants and strategic investment.
To date, we have secured over AUD 13 million in grant funding, with a further AUD 9 million committed, from leading global and national organizations including NIH, BARDA, CEPI, IDRC, NSW Government, and Meat & Livestock Australia. This non-dilutive funding reflects significant external validation of our science and has enabled rapid advancement of our RNA vaccine and therapeutic programs.
Complementing this, Tiba has raised AUD 7 million in equity investment from a diversified investor base, including a specialist life sciences venture fund, a global contract research organization (CRO), and multiple high-net-worth individuals with deep sector expertise.
We are now seeking AUD 1.5 million in convertible notes to bridge into a AUD 9 million Series A round, which will enable new hires and accelerate clinical development of our human health pipeline and unlock near-term commercial opportunities.
Terra Australis Pharmaceuticals
Naturally discovered on Kangaroo Island, AUS_001 is being developed by Terra Australis Pharmaceuticals PTY Ltd and is targeting the very worst of cancers including pancreatic, GBM and DMG/DIPG.
Avecho
Immuron (ASX:IMC | NASDAQ:IMRN)
Immuron Limited (ASX:IMC | NASDAQ:IMRN) is a dual-listed Australian biopharmaceutical company transforming how infectious diseases are prevented and treated.
Using a proprietary oral antibody platform, Immuron delivers clinically backed therapies that act directly in the gut — including Travelan®, a market-leading product targeting travellers’ diarrhea.
With global commercial traction, a differentiated technology base, and a pipeline addressing high-impact health challenges, Immuron is advancing a new frontier in accessible, gut-targeted health solutions.
Pitching companies 2025
